Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In idiopathic Parkinson's disease massive cell death occurs in the dopamine-containing substantia nigra. A link between the vulnerability of nigral neurons and the prominent pigmentation of the substantia nigra, though long suspected, has not been proved. This possibility is supported by evidence that N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite MPP+, the latter of which causes destruction of nigral neurons, bind to neuromelanin. We have directly tested this hypothesis by a quantitative analysis of neuromelanin-pigmented neurons in control and parkinsonian midbrains. The findings demonstrate first that the dopamine-containing cell groups of the normal human midbrain differ markedly from each other in the percentage of neuromelanin-pigmented neurons they contain. Second, the estimated cell loss in these cell groups in Parkinson's disease is directly correlated (r = 0.97, P = 0.0057) with the percentage of neuromelanin-pigmented neurons normally present in them. Third, within each cell group in the Parkinson's brains, there is greater relative sparing of non-pigmented than of neuromelanin-pigmented neurons. This evidence suggests a selective vulnerability of the neuromelanin-pigmented subpopulation of dopamine-containing mesencephalic neurons in Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The nigra’s neuromelanin derives from dopamine and occurs in autolysosomes rather than melanosomes (226).”
From Chemiexcitation: Mammalian Photochemistry in the Dark† (2023) · cites this paper as [226]
In the citing paper
“The concept of such a substantial loss of EC neurons before AD symptoms occur may be analogous to the observation that very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
In the citing paper
“very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
Citations
Cites
Dahlstroem, A., & Fuxé, K. (1964) · PubMed · Cited by 5,133
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
STEELE, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,924
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Emson, P., Heffher, R. R., & Pearson, J. (1984) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198409000-00010 · Cited by 1,648
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Gerfen, C., Herkenham, M., & Thibault, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 803
Hirsch, E. C., Graybiel, A. M., Duyckaerts, C., & Javoy-Agid, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5976 · Cited by 554
Self-citation
Research works printed but not linked: 6
- Escourolle, R., De Recondo, J. & Gray, F. in Monoamines Noyaux gris cenlraux et syndromes de Parkinson (eds de Ajuriaguerra, J. & Gauthier, G.) 173–229 (Geneva, 1970).
- Marsden, C. D. J. Neural Trans. Suppl. 19, 121–141 (1983).
- Dahlström, A. & Fuxe, K. Acta physiol. scand. 62, (Suppl. 232) 1–55 (1964).
- Graybiel, A. M. & Ragsdale, C. W. Jr in Chemical Neuroanalomy (ed. Emson, P. C.) 427–504 (Raven, New York, 1983).
- Graham, D. G. Molec. Pharmacol. 14, 633–643 (1978).
- Lindquist, N. G. Acta radiol. Suppl. 325, 1–92 (1973).
Cited by
Items 501–600 of 1,000
Long-term effects of ionising radiation on the brain: cause for concern?
Kempf, S. J., Azimzadeh, O., Atkinson, M. J., & Tapio, S. (2012) · Radiation and Environmental Biophysics · doi:10.1007/s00411-012-0436-7 · Cited by 60
“lation of dopaminergic neurons in the substantia nigra pars compacta (Snpc) (Hirsch et al. 1988).”
BackgroundGhrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
dos Santos, V. V., Rodrigues, A. L. S., de Lima, T. C. M., de Barioglio, S. R., Raisman‐Vozari, R., & Prediger, R. D. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990411 · Cited by 57
Zhou, P., Homberg, J. R., Fang, Q., Wang, J., Li, W., Meng, X., Shen, J., Luan, Y., Liao, P., Swaab, D. F., et al. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.11.006 · Cited by 56
“Parkinson's disease (PD) goes together with a progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) (Hirsch et al., 1988; Damier et al., 1999).”
Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice
Yokoyama, H., Takagi, S., Watanabe, Y., Kato, H., & Araki, T. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0019-6 · Cited by 53
“Parkinson’s disease (PD) is a progressive and age-related neurodegenerative disease characterized by degeneration of dopaminergic neurons localized in the substantia nigra pars compacta and striatum ( Hirsh et al. 1988 ).”
BackgroundCruz‐Muros, I., Afonso‐Oramas, D., Abreu, P. M., Barroso‐Chinea, P., Rodríguez, M., González, M. C., & González‐Hernández, T. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.10.004 · Cited by 53
Ulusoy, A., & Monte, D. A. D. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8329-y · Cited by 55
“Dopaminergic cells in the substantia nigra pars compacta (SNpc) are distinctively targeted by neurodegenerative processes as indicated, for example, by their greater susceptibility to die in PD as compared with dopaminergic neurons in the nearby ventral tegmental area (VTA) [45, 46].”
BackgroundDiacylglycerol kinase as a possible therapeutic target for neuronal diseases
Shirai, Y., & Saito, N. (2014) · Journal of Biomedical Science · doi:10.1186/1423-0127-21-28 · Cited by 56
The locus coeruleus: Another vulnerability target in Parkinson's disease
Oertel, W. H., Henrich, M. T., Janzen, A., & Geibl, F. F. (2019) · Movement Disorders · doi:10.1002/mds.27785 · Cited by 56
“alterations of LC neurons and the final cell loss during advanced disease stages leaves the LC for many years in a dysfunctional state.(1,15,20) It is therefore tempting to speculate that LC neurons may have so far unidentified intrinsic resilient properties, which render them partially resistant to the disease proces…”
Backgroundvan Rensburg, Z. J., Abrahams, S., Bardien, S., & Kenyon, C. P. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02516-5 · Cited by 56
“Therefore, the increased loss of neuromelanin in individuals living with PD when compared to healthy controls, is most likely due to the increased loss of dopaminergic neurons in PD [83, 127, 141].”
BackgroundLitteljohn, D., Mangano, E. N., & Hayley, S. P. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06371.x · Cited by 54
Waldmeier, P. C., Buchle, A.-M., & Steulet, A.-F. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90222-i · Cited by 51
Michel, P. P., Vyas, S., & Agid, Y. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08882.x · Cited by 54
“In addition, the selective vulnerability of dopaminergic neurons to iron may be closely related to the presence of DA, the neurotransmitter occumng naturally within this cell type, and to that of neuromelanin, its nonenzymatic metabolic waste product (Hirsch et al., 1988; Youdim et al., 1989), especially because iron,…”
BackgroundSelf-citationElstner, M., Müller, S. K., Leidolt, L., Laub, C., Krieg, L., Schlaudraff, F., Liss, B., Morris, C., Turnbull, D. M., Masliah, E., et al. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-43 · Cited by 50
Lennington, J. B., Pope, S., Goodheart, A. E., Drozdowicz, L., Daniels, S. B., Salamone, J. D., & Conover, J. C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1197-11.2011 · Cited by 50
“While the loss of SNpc dopamine neurons and subsequent motor dysfunction are hallmarks of Parkinson’s disease, analysis of the midbrain from patients shows not only an average of 76% reduction in SNpc A9 neurons, but also declines of 48% in VTA A10 dopamine neurons (Hirsch et al., 1988).”
BackgroundChapter VI Dopamine systems in the primate brain
Lewis, D. A., & Sesack, S. R. (1997) · Handbook of chemical neuroanatomy · doi:10.1016/s0924-8196(97)80008-5 · Cited by 71
Pathogenesis and preclinical course of Parkinson’s disease
Foley, P., & Riederer, P. F. (1999) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6360-3_2 · Cited by 64
Bankiewicz, K. S. (2003) · Frontiers in bioscience · doi:10.2741/1104 · Cited by 50
“susceptibility in all of the cell groups which project to the striatum (14, 15, 67).”
BackgroundChiueh, C. C., Huang, S. ‐., & Murphy, D. L. (1994) · Springer eBooks · doi:10.1007/978-3-7091-9324-2_25 · Cited by 61
Neuropathology of α‐synuclein in Parkinson's disease
Choong, C., & Mochizuki, H. (2022) · Neuropathology · doi:10.1111/neup.12812 · Cited by 60
Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
Mihaescu, A. S., Valli, M., Uribe, C., Díez‐Cirarda, M., Masellis, M., Graff‐Guerrero, A., & Strafella, A. P. (2022) · Molecular Brain · doi:10.1186/s13041-022-00964-1 · Cited by 60
“While the etiology of the motor deficits is generally understood [3, 4], the underlying cause of cognitive decline in PD remains elusive [1, 5].”
BackgroundDopaminergic neuron metabolism: relevance for understanding Parkinson’s disease
Flores-Ponce, X., & Velasco, I. (2024) · Metabolomics · doi:10.1007/s11306-024-02181-4 · Cited by 61
“(Alberico et al., 2015; Damier et al., 1999; Hirsch et al., 1988; Sur-meier et al., 2017 ).”
BackgroundLRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation
Prabhudesai, S. N., Bensabeur, F., Abdullah, R., Basak, I., Baez, S., Alves, G. W., Holtzman, N. G., Larsen, J. P., & Møller, S. G. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23754 · Cited by 53
“PD is characterized by degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta and a reduction of striatial DA levels (Hirsch et al., 1988).”
BackgroundRaha, A. A., Biswas, A., Henderson, J. W., Chakraborty, S., Holland, A. J., Friedland, R. P., Mukaetova‐Ladinska, E. B., Zaman, S. H., & Raha‐Chowdhury, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031060 · Cited by 55
“The population of pigmented neurons composed of neuromelanin in substantia nigra (SN) is the main target of the neurodegenerative process in PD [45,46].”
BackgroundPike, A. F., Szabó, I., Veerhuis, R., & Bubacco, L. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00293-z · Cited by 52
“substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders.”
BackgroundKästner, A., Herrero, M. T., Hirsch, É. C., López-Guillén, J. L., Luquín, M. R., Javoy-Agid, F., Obeso, J. A., & Agid, Y. (1994) · Annals of Neurology · doi:10.1002/ana.410360213 · Cited by 49
Self-citationChinaglia, G., Probst, A., & Palacios, J. M. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90273-7 · Cited by 52
Veenvliet, J. V., & Smidt, M. P. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1681-5 · Cited by 51
“Although the specific vulnerability and degeneration of SNc neurons in PD was acknowledged long ago [1, 216, 217], the”
Fa, Z., & Dryhurst, G. (1995) · Journal of Electroanalytical Chemistry · doi:10.1016/0022-0728(95)04219-7 · Cited by 53
Rasagiline: an anti-Parkinson drug with neuroprotective activity
Youdim, M. B. (2003) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.3.6.737 · Cited by 48
Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells
Shamoto‐Nagai, M., Maruyama, W., Akao, Y., Osawa, T., Tribl, F., Gerlach, M., Zucca, F. A., Zecca, L., Riederer, P. F., & Naoi, M. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0211-2 · Cited by 56
“, 1998; Mann and Yates, 1974), suggesting that NM may be involved in the vulnerability of these neurons (Hirsch et al., 1988; Kastner et al., 1992).”
BackgroundHuman-based studies on α-synuclein deposition and relationship to Parkinson's disease symptoms
Halliday, G. M., & McCann, H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.006 · Cited by 56
Faucheux, B. A., Hauw, J., Agid, Y., & Hirsch, É. C. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01412-6 · Cited by 52
Self-citationBen‐Shachar, D., & Youdim, M. B. H. (1990) · Springer eBooks · doi:10.1007/978-3-7091-9050-0_24 · Cited by 59
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
Parsanejad, M., Bourquard, N., Qu, D., Zhang, Y., Huang, E., Rousseaux, M. W. C., Aleyasin, H., Irrcher, I., Callaghan, S. M., Vaillant, D. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106601 · Cited by 51
“PD is a progressive neurodegenerative disorder characterized by selective loss of the pigmented dopaminergic neurons of the Substantia nigra pars compacta (SNc) [1], and reduction in striatal dopamine level.”
BackgroundRotenone induced neurotoxicity in rat brain areas: A histopathological study
Swarnkar, S., Singh, S., Sharma, S., Mathur, R., Patro, I. K., & Nath, C. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.03.036 · Cited by 47
Ma, S. Y., Rinne, J. O., Collan, Y. U., Röyttä, M., & Rinne, U. K. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00069-x · Cited by 47
Thuret, S., Alavian, K. N., Gassmann, M., Lloyd, K. C. K., Smits, S. M., Smidt, M. P., Klein, R., Dyck, R. H., & Simon, H. H. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02809.x · Cited by 47
“and to determine subpopulations in these cell groups by several criteria (Hirsch et al. 1988; Jimenez-Castellanos and Graybiel 1989b; Hirsch et al. 1997).”
Viereckel, T., Dumas, S., Smith-Anttila, C. J. A., Vlcek, B., Bimpisidis, Z., Lagerström, M. C., Konradsson-Geuken, Å., & Wallén-Mackenzie, Å. (2016) · Scientific Reports · doi:10.1038/srep35203 · Cited by 45
Potential Role of Heterocyclic Aromatic Amines in Neurodegeneration
Syeda, T., & Cannon, J. R. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00274 · Cited by 49
Hemoglobin is present as a canonical α2β2 tetramer in dopaminergic neurons
Russo, R., Zucchelli, S., Codrich, M., Marcuzzi, F., Verde, C., & Gustincich, S. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.05.005 · Cited by 47
“In the brain, Hb can be detected in mesencephalic A9 dopaminergic neurons,whose selective degeneration is the primary cause of Parkinson's disease [14], in cortical and hippocampal astrocytes as well as in virtually allmature oligodentrocytes [6].”
BackgroundProbucol Affords Neuroprotection in a 6-OHDA Mouse Model of Parkinson’s Disease
Ribeiro, R. P., Moreira, E. L. G., Santos, D. B., Colle, D., dos Santos, A. A., Peres, K. C., Figueiredo, C. P., & Farina, M. (2013) · Neurochemical Research · doi:10.1007/s11064-012-0965-0 · Cited by 49
Manfredsson, F. P., Okun, M. S., & Mandel, R. J. (2009) · Current Gene Therapy · doi:10.2174/156652309789753400 · Cited by 48
“, in PD, there are more nigral TH+ neurons remaining than neuromelanin containing SN neurons [93] and this ratio between nigral pigmented DA neurons and TH+ neurons holds in the aging brain as well [94].”
BackgroundBensaid, M., Michel, P. P., Clark, S. D., Hirsch, É. C., & François, C. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.11.004 · Cited by 47
“This is coherentwith the fact that the rate-limiting enzyme in dopamine synthesis, tyrosine hydroxylase, whose expression is activity- and calcium-dependent (Brosenitsch and Katz, 2001), is absent from a large fraction of neuromelanized DA neurons in PD brains (Hirsch et al., 1988).”
Plum, S., Steinbach, S., Attems, J., Keers, S. M., Riederer, P. F., Gerlach, M., May, C., & Marcus, K. (2016) · Scientific Reports · doi:10.1038/srep37139 · Cited by 50
Ferrari, E., Capucciati, A., Prada, I., Zucca, F. A., D’Arrigo, G., Pontiroli, D., Bridelli, M. G., Sturini, M., Bubacco, L., Monzani, E., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00231 · Cited by 49
Stem-Cell-Based Strategies for the Treatment of Parkinson’s Disease
Parish, C. L., & Arenas, E. (2007) · Neurodegenerative Diseases · doi:10.1159/000101892 · Cited by 46
“The principal pathology underlying PD is the loss of pigmented dopaminergic (DA) neurons of the midbrain. Death of these cells results in DA depletion within the target striatum, causing the classical movement anomalies associated with the disease such as bradykinesia/akinesia, postural changes and resting tremor [”
BackgroundIron transport in Parkinson's disease
Hirsch, É. C. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70816-8 · Cited by 52
“Indeed, dopamine metabolism, and in particular the production in neuromelanin, found in the most vulnerable neurons, is associated with the production of oxygen free radicals under physiological conditions [8].”
BackgroundNeuromelanin synthesis in rat and human substantia nigra
Rabey, J. M., & Hefti, F. F. (1990) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02251241 · Cited by 46
“Given the fact that neuromelanin containing ceils degenerate selectively in Parkinson's disease ( Hirsch et al., 1988 ) and that neuromelanin is abundant in humans and other primates but not in rat substantia nigra, we decided to further study the "in vitro" synthesis of neuromelanin in tissue from both species.”
BackgroundInfluentialMelanin affinity and its possible role in neurodegeneration
Karlsson, O., & Lindquist, N. G. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1062-5 · Cited by 55
Kannan, P. K., Moshkalev, S. A., & Rout, C. S. (2016) · Nanotechnology · doi:10.1088/0957-4484/27/7/075504 · Cited by 45
Li, Q., Mo, J., Xiong, B., Liao, Q., Chen, Y., Wang, Y., Xing, S., He, S., Lyu, W., Zhang, N., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00560 · Cited by 54
Liu, C., Chen, Z., Liu, F.-X., Hu, D.-N., & Luo, J. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.08.014 · Cited by 45
Chocyk, A., Przyborowska, A., Dudys, D., Majcher‐Maślanka, I., Maćkowiak, M., & Wędzony, K. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.03.008 · Cited by 49
Basal ganglia dopamine loss due to defect in purine recycling
Egami, K., Yitta, S., Kasim, S., Lewers, J. C., Roberts, R. C., Lehar, M., & Jinnah, H. A. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.01.010 · Cited by 47
Fang, X., Sugiyama, K., Akamine, S., & Namba, H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.073 · Cited by 48
Alladi, P. A., Mahadevan, A., Vijayalakshmi, K., Muthane, U. B., Shankar, S. K., & Raju, T. R. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.06.018 · Cited by 44
Benisty, S., Boissière‐Michot, F., Faucheux, B. A., Agid, Y., & Hirsch, É. C. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00126-2 · Cited by 54
Self-citationRugg, E. L., Dunbar, J. S., Latimer, M., & Winn, P. (1992) · Brain Research · doi:10.1016/0006-8993(92)91277-l · Cited by 46
Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease
Huynh, B., Fu, Y., Kirik, D., Shine, J. M., & Halliday, G. M. (2021) · Movement Disorders · doi:10.1002/mds.28615 · Cited by 50
“A diverse proportion of both noradrenergic and dopaminergic neuronal populations contain neuromelanin pigment in humans, a finding that has been directly linked with greater vulnerability to PD.(18,19) Pigmented catecholaminergic neurons reduce their capacity to synthesize catecholamines before cell death,(15,20,21) a…”
BackgroundInfluentialKlaissle, P., Lesemann, A., Huehnchen, P., Hermann, A., Storch, A., & Steiner, B. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-132 · Cited by 54
Selective loss of nigral neurons in Alzheimer's disease: a morphometric study
Uchihara, T., Kondo, H., Kosaka, K., & Tsukagoshi, H. (1992) · Acta Neuropathologica · doi:10.1007/bf00296789 · Cited by 45
“In Parkinson's disease, pigmented neurons, especially in the ventrolateral cell group, are reportedly most severely affected [1, 6, 7, 9, 10, 12 , 18, 27, 28, 30].”
BackgroundKlein, A., Wessolleck, J., Papazoglou, A., Metz, G. A. S., & Nikkhah, G. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.007 · Cited by 49
Zhang, J., Yang, B., Sun, H., Zhou, Y., Liu, M., Ding, J., Fang, F., Fan, Y., & Hu, G. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.12.057 · Cited by 46
Parain, K., Marchand, V., Dumery, B., & Hirsch, É. C. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03198-x · Cited by 44
Depboylu, C., Schorlemmer, K., Klietz, M., Oertel, W. H., Weihe, E., Höglinger, G. U., & Schäfer, M. K.-H. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.05.006 · Cited by 46
“…characterized by an akineticrigid syndrome related to reduced dopamine (DA) levels in the striatum (Bernheimer et al., 1973) due to progressive loss of terminals of degenerating neuromelanin (NM)-containing DAergic neurons in the substantia nigra pars compacta (SNc) (Hirsch et al., 1988).”
BackgroundOxidation Chemistry of (−)-Norepinephrine in the Presence of l -Cysteine
Shen, X.-M., & Dryhurst, G. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960016t · Cited by 48
Youdim, M. B. H., Ben‐Shachar, D., & Riederer, P. F. (1990) · Springer eBooks · doi:10.1007/978-3-7091-9113-2_34 · Cited by 53
Gaertner, Z. A., Azcorra, M., Dombeck, D. A., & Awatramani, R. B. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105925 · Cited by 48
“Secondly, the degree of neuromelanin pigmentation of a given region is directly correlated to the degree of degeneration, and finally that the substantia nigra is selectively degenerated relative to other less-pigmented DA clusters such as the VTA or DA neurons of the hypothalamus – a pattern soon confirmed by other g…”
BackgroundCombinatory microRNA serum signatures as classifiers of Parkinson's disease
Patil, K. S., Basak, I., Dalen, I., Hoedt, E., Lange, J., Lunde, K. A., Liu, Y., Tysnes, O., Forsgren, L., Aarsland, D., et al. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.04.010 · Cited by 43
“Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, characterized by neuronal cell death and Lewy bodies formation[1].”
BackgroundDifferential leukocyte count is associated with clinical phenotype in Parkinson's disease
Umehara, T., Oka, H., Nakahara, A., Matsuno, H., & Murakami, H. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.116638 · Cited by 43
Buck, S. A., Steinkellner, T., Aslanoglou, D., Villeneuve, M., Bhatte, S. H., Childers, V. C., Rubin, S. A., Miranda, B. R. D., O’Leary, E. I., Neureiter, E. G., et al. (2021) · Aging Cell · doi:10.1111/acel.13365 · Cited by 50
Hayashi, S., Wakabayashi, K., Ishikawa, A., Nagai, H., Saito, M., Maruyama, M., Takahashi, T., Ozawa, T., Tsuji, S., & Takahashi, H. (2000) · Movement Disorders · doi:10.1002/1531-8257(200009)15:5<884::aid-mds1019>3.0.co;2-8 · Cited by 212
NEUROANATOMY OF THE BASAL GANGLIA
Mello, L. E., & Villares, J. (1997) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70340-3 · Cited by 53
Voltage-gated calcium channels and Parkinson's disease
Hurley, M. J., & Dexter, D. T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.006 · Cited by 55
Salthun-Lassalle, B., Traver, S., Hirsch, É. C., & Michel, P. P. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015453 · Cited by 43
“The effect of the tachykinin agonists might be simply to restore the expression of TH within neurons that contain undetectable amounts of the enzyme as they entered a premorbid state (Hirsch et al., 1988; Michel and Agid, 1996).”
BackgroundSubcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle
Tribl, F., Marcus, K., Meyer, H. E., Bringmann, G., Gerlach, M., & Riederer, P. F. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0452-3 · Cited by 46
“It is well established that especially the pigmented neurons are very susceptible to degeneration in PD depending on the extent of pigmentation (Hirsch et al., 1988).”
BackgroundResultKropf, A. J., Bunker, B. A., Eisner, M., Moss, S. C., Zecca, L., Stroppolo, A., & Crippa, P. R. (1998) · Biophysical Journal · doi:10.1016/s0006-3495(98)77755-0 · Cited by 43
“In normal subjects NM accumulates with age, reaching a maximum between ages 60 and 70, while in patients afflicted with Parkinson’s disease a loss of highly pigmented dopamine neurons is observed (Hirsch et al., 1988; Gibb, 1992).”
BackgroundThe degeneration and replacement of dopamine cells in Parkinson’s disease: the role of aging
Rodríguez, M., Moráles, I., Rodriguez‐Sabate, C., Sánchez, A., Castro, R., Armas, J. M. B., & Sabaté, M. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00080 · Cited by 52
Bulteau, A., Mena, N. P., Auchère, F., Lee, I., Prigent, A., Lobsiger, C. S., Camadro, J., & Hirsch, É. C. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.03.036 · Cited by 45
Neuromelanin in parkinsonian disorders: an update
Martín‐Bastida, A., Pietracupa, S., & Piccini, P. P. (2017) · International Journal of Neuroscience · doi:10.1080/00207454.2017.1325883 · Cited by 45
Wang, C., Sun, Z., Wang, M., & Zhang, C. (2017) · Cell Biology International · doi:10.1002/cbin.10864 · Cited by 42
[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP
Coakeley, S., Cho, S. S., Koshimori, Y., Rusjan, P., Ghadery, C., Kim, J., Lang, A. E., Houle, S., & Strafella, A. P. (2017) · Brain Structure and Function · doi:10.1007/s00429-017-1507-y · Cited by 45
“…within the substantia nigra pars compacta contain varying levels of neuromelanin and many studies have shown that cells containing higher levels of neuromelanin are more susceptible to neurodegeneration (Mann and Yates 1983; Hirsch et al. 1988; Kastner et al. 1992; Dauer and Przedborski 2003).”
BackgroundEarly fine motor impairment and behavioral dysfunction in (Thy‐1)‐h[A30P] alpha‐synuclein mice
Ekmark‐Lewén, S., Lindström, V., Gumucio, A., Ihse, E., Behere, A., Kahle, P. J., Nordström, E. K. L., Eriksson, M., Erlandsson, A., Bergström, J. J. E., et al. (2018) · Brain and Behavior · doi:10.1002/brb3.915 · Cited by 42
Diet and medical foods in Parkinson’s disease
Lange, K. W., NAKAMURA, Y., Chen, N., Guo, J., Kanaya, S., Lange, K. M., & Li, S. (2019) · Food Science and Human Wellness · doi:10.1016/j.fshw.2019.03.006 · Cited by 51
Glutamate homeostasis and dopamine signaling: Implications for psychostimulant addiction behavior
Fischer, K. D., Knackstedt, L. A., & Rosenberg, P. A. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104896 · Cited by 44
MATHEUS, F. C., Aguiar, A. S., de Castro, A. A., Villarinho, J. G., Ferreira, J., Figueiredo, C. P., Walz, R., Santos, A. R. S., Tasca, C. I., & Prediger, R. D. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.08.017 · Cited by 41
Sasajima, H., Miyazono, S., Noguchi, T., & Kashiwayanagi, M. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2015.10.006 · Cited by 43
“…of dopaminergic neurons in the substantia nigra (Betarbet et al., 2000; Fleming et al., 2004; Greenamyre et al., 2003; Sherer et al., 2003; Zhu et al., 2004), where dopaminergic neurons are particularly sensitive to the mitochondrial ROS in the brain (Damier et al., 1999; Hirsch et al., 1988).”
BackgroundThibaut, F., Faucheux, B. A., Marquez, J., Villares, J., Ménard, J.-F., Agid, Y., & Hirsch, É. C. (1995) · Brain Research · doi:10.1016/0006-8993(95)00674-f · Cited by 43
Self-citationBlood vessels and Parkinsonism
Barcia, C. (2004) · Frontiers in Bioscience · doi:10.2741/1145 · Cited by 41
“The highest degree of cell death occurs in the Substantia Nigra pars compacta (SNpc) (80-90%) (1), whereas a lesser degree is encountered in the ventral tegmental area (VTA) and in the peri- and retro-rubral catecholaminergic group (A8) (30-50%), and minimal loss is present in the periaqueductal grey matter (PAG) (3%)…”
BackgroundChurchill, M. J., Pflibsen, L. R., Sconce, M. D., Moore, C., Kim, K., & Meshul, C. K. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.07.031 · Cited by 47
“Over activation of microglia can hinder tissue regeneration and recovery after a lesion (Hirsch et al 1988, Hirsch et al 2009, Derecki et al 2013).”
BackgroundNeuroprotective Effect ofCoptis chinensisin MPP+ and MPTP-Induced Parkinson’s Disease Models
Friedemann, T., Ying, Y., Wang, W., Kramer, E. R., Schumacher, U., Fei, J., & Schröder, S. (2016) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x16500506 · Cited by 45
Neuromelanin in Parkinson’s Disease: from Fenton Reaction to Calcium Signaling
Knörle, R. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9804-z · Cited by 41
“Such a selective vulnerability of the NM-pigmented subpopulation of dopaminergic neurons in PD has been shown histochemically (Hirsch et al. 1988).”
BackgroundDistribution of semaphorin IV in adult human brain
Hirsch, É. C., Hu, L., Prigent, A., Constantin, B., Agid, Y., Drabkin, H. A., & Roche, J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01103-8 · Cited by 40
Self-citationLee, S. Y., Moon, Y., Hee Choi, D., Jin Choi, H., & Hwang, O. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.024 · Cited by 40
Kosinski, C. M., Standaert, D. G., Counihan, T. J., Scherzer, C. R., Kerner, J. A., Daggett, L. P., Veli�elebi, G., Penney, J. B., Young, A. B., & Landwehrmeyer, G. B. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980105)390:1<63::aid-cne6>3.0.co;2-o · Cited by 63
Neurotoxicity and neuroprotection in Parkinson's disease
Lange, K. W., Youdim, M. B. H., & Riederer, P. F. (1992) · PubMed · doi:10.5283/epub.25435 · Cited by 51
Dopamine modulation of spatial navigation memory in Parkinson's disease
Thurm, F., Schuck, N. W., Fauser, M., Doeller, C. F., Stankevich, Y., Evens, R., Riedel, O., Storch, A., Lueken, U., & Li, S. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.019 · Cited by 46
“, 1991), which might in part be related to the shift in navigation strategies in older age, the dorsal striatum (including the caudate nucleus) is further affected by pathology-related DA depletion already during early PD (Damier et al., 1999; Hirsch et al., 1988; Pham et al., 2012; Reyes et al., 2013).”
InfluentialMapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia
Rice, M. W., Roberts, R. C., Meléndez‐Ferro, M., & Pérez‐Costas, E. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0901-y · Cited by 47
“…for total neurons as well as dopaminergic neurons, in schizophrenia and control samples, were comparable to previous reports in which estimates were obtained from the entire SN/VTA (Bogerts et al. 1983; Hirsch et al. 1988; van Domburg and ten Donkelaar 1991; Damier et al. 1999a; Rudow et al. 2008).”
Briceño, A., Muñoz, P., Brito, P., Huenchuguala, S., Segura‐Aguilar, J., & Paris, I. B. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9560-x · Cited by 41
Metadata
- Authors
- Hirsch, E., Graybiel, A. M., & Agid, Y. A.
- Affiliations
- Massachusetts Institute of Technology (US)
- Inserm (FR)
- ORCID
- Graybiel, Ann M.
- Venue
- Nature
- Published
- 1988-07
- Volume
- 334
- Issue
- 6180
- Pages
- 345-348
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2054421268
- Semantic Scholar
- a3233ab8e74d927c8cdec03d6fc967cde7332aaf
- Cited by
- 1,301
- References
- 20
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 29 · 2023: 35 · 2022: 47 · 2021: 51 · 2020: 48 · 2019: 45 · 2018: 37 · 2017: 34 · 2016: 48 · 2015: 49 · 2014: 47 · 2013: 43 · 2012: 50
- FWCI
- 23.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, neuromelanin, dopaminergic neurons, substantia nigra, neuronal vulnerability, MPTP, MPP+, selective neuronal degeneration, midbrain, cell loss
- MeSH terms
- Acetylcholinesterase, Dopamine, Humans, Melanins, Nerve Degeneration, Neurons, Parkinson Disease, Pyridines, Pyridinium Compounds, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1-Methyl-4-phenylpyridinium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.